July 11, 2006 NASD OTC-BB: MRDAF

Meridian Files Patent Application Under the Patent Cooperation Treaty

Meridian Co., Ltd. ("Meridian") (OTC BB:MRDAF.OB - News) announced today that it has filed an international provisional patent application under the Patent Cooperation Treaty for adipose resolve apparatus for low powered laser treatments, which relates to the Company's proprietary Lipo-Laser system.

The Patent Cooperation Treaty provides a unified procedure for filing patent applications to protect inventions internationally. Currently there are 128 member countries of the Patent Cooperation Treaty.

The intellectual property relating to the Lipo-Laser system has already been patented in Korea, which potentially suggests that the patent application under the Patent Cooperation Treaty will be accepted in a short period of time.

The Lipo-Laser was designed to target the aesthetic market. Despite strong recent growth, the marketplace for aesthetic procedures continues to expand. This appears to be driven by a large population of aging baby boomers, continued strong consumer spending enabled by a healthy economy and the introduction of increasingly efficacious procedures that offer better results with minimal downtime. The Lipo-Laser's non-invasive treatment is considered one of the most innovative methods to reduce the appearance of cellulite and improve body contour.

The demand for this type of treatment is expected to grow rapidly, not only in the plastic surgery profession but in any clinical setting such as spas and wellness centers that treat localized body fat deposits which may not have responded to diet and exercise.

Light-based treatments are now the mainstays of medical aesthetic practices. In 2004, over twenty six million hair removal, skin rejuvenation, tattoo and pigmented lesion removal, acne reduction, vascular lesion and other treatments were performed. These treatments earned more than 8 billion dollars for practitioners and almost 550 million dollars for equipment manufacturers. By 2009, this is expected to grow to over eighty four million treatments annually earning practitioners 13.9 billion dollars and manufacturers nearly 1 billion dollars.

Concurrent with the recent 510(k) submission to the FDA regarding acceptance in the US market, the submission of the patent application to the Patent Cooperation Treaty is an important milestone in advancing the Company's business plan to commercialize its proprietary products and enhance over all financial performance.

More About: Meridian

Meridian is an established leader in the research/development, manufacturing, and sales of integrative medical diagnostic equipment. The company sells its products and equipment to a wide array of customers in the global health care industry. The company presently holds a total of 18 worldwide patents on its technology, and has received FDA, as well as other international regulatory approvals for many of its products.

Meridian is committed to the ongoing global research and advancement of integrative medical products that contribute to the better health of humanity.

On Behalf of the Board of Directors,

Hyeon Seong Myeong, President

This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the company.

Contacts:

Contacts:
Belgium Medical Inc.
Tariq Tyab
1-877-738-8119

Belgium Medical Inc.
Peter Holeczek
Corporate Communications
1-866-736-3306
https://MeridianMedical.ca